BC Innovations | Apr 24, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest CAR T cells targeting GD2 could help treat diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas harboring the H3.3A K27M mutation. In co-culture with...
BC Innovations | Dec 19, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice with p53 knocked out, ATRX knocked down and both PDGFRA and K27M-mutant H3.3A overexpressed could be useful for screening therapies to treat pediatric high-grade gliomas. In mice, embryos engineered in...
BC Innovations | Dec 19, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer In vitro and mouse studies suggest T cells expressing a tumor-specific TCR could help treat glioma harboring the K27M mutation of H3.3A. In a co-culture of human T cells and H3.3A K27M-mutant...
BC Innovations | May 9, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer H3 histone family 3A (H3.3A; H3F3A); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC); checkpoint kinase 1 (Chk1); aurora kinase A (AURKA;...
BC Innovations | Apr 11, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer H3 histone family 3A (H3.3A; H3F3A); histone cluster 1 H3b (HIST1H3B); polycomb repressive complex 2 (PRC2) In vitro and...
Items per page:
1 - 5 of 5